Actavis to Present at Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 - WSFA.com: News Weather and Sports for Montgomery, AL.

Actavis to Present at Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Actavis plc

DUBLIN, May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 in New York City.

The presentation will take place on Thursday, May 29, 2014 at 10:00 a.m. Eastern Time at the Waldorf-Astoria Hotel, 301 Park Avenue, New York, NY.  To access a live webcast of the presentation, visit Actavis' Investor Relations Web site at http://ir.actavis.com.  The webcast can also be accessed at the following URL:
http://cc.talkpoint.com/bern001/052814a_bb/?entity=37_M7YRGDP

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Actavis

Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  Actavis has global headquarters in Dublin, Ireland and U.S. administrative headquarters in Parsippany, New Jersey, USA. 

Actavis develops and manufactures generic, brand, branded generic, legacy brands and Over-the-Counter (OTC) pharmaceutical products and has commercial operations in approximately 60 countries.  The Company's North American branded pharmaceuticals business is focused principally in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories with a strong pipeline of products in various stages of development.  Actavis also has a portfolio of five biosimilar products in development in Women's Health and Oncology.  Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.

For press release and other company information, visit Actavis' Web site at http://www.actavis.com

CONTACTS:

Investors:
Lisa DeFrancesco
(862) 261-7152

Media:
Charlie Mayr
(862) 261-8030

David Belian
(862) 261-8141

Actavis plc logo.

 

Logo- http://photos.prnewswire.com/prnh/20130124/NY47381LOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow